EAM
AIMT

Eventide Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Eventide Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,193,117
Closed -$53.4M – 154
2020
Q2 		$53.4M Sell
3,193,117
-657,883
-17% -$11.2M 1.16% 29
2020
Q1 		$55.5M Buy
3,851,000
+767,000
+25% +$19.6M 1.8% 13
2019
Q4 		$103M Hold
3,084,000
– – 2.91% 5
2019
Q3 		$64.6M Buy
3,084,000
+309,000
+11% +$6.31M 2.13% 11
2019
Q2 		$57.8M Buy
2,775,000
+813,000
+41% +$16.7M 1.76% 14
2019
Q1 		$43.9M Buy
1,962,000
+223,000
+13% +$5.25M 1.51% 17
2018
Q4 		$41.6M Hold
1,739,000
– – 1.84% 13
2018
Q3 		$47.4M Buy
1,739,000
+119,000
+7% +$3.37M 1.74% 15
2018
Q2 		$43.6M Buy
1,620,000
+55,017
+4% +$1.68M 1.81% 11
2018
Q1 		$49.8M Buy
1,564,983
+338,983
+28% +$11.9M 2.33% 5
2017
Q4 		$46.4M Buy
1,226,000
+196,000
+19% +$6.32M 2.42% 8
2017
Q3 		$25.5M Hold
1,030,000
– – 1.45% 27
2017
Q2 		$21.2M Buy
1,030,000
+720,000
+232% +$13.7M 1.32% 33
2017
Q1 		$6.74M Buy
+310,000
New +$6.36M 0.45% 60

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Eventide Asset Management's AIMT Position: Q3 2020 in Review

Eventide Asset Management sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 3,193,117 shares — an estimated $53.4M sold.

Eventide Asset Management first reported a position in AIMT in Q1 2017 and held it in 14 quarters. The position peaked at $103M in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Eventide Asset Management reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Eventide Asset Management sold 3,193,117 Aimmune Therapeutics shares in Q3 2020, an estimated $53.4M.
  • Eventide Asset Management first reported a position in Aimmune Therapeutics in Q1 2017 and held it in 14 quarters.
  • Eventide Asset Management's Aimmune Therapeutics position peaked at $103M in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Eventide Asset Management's 13F filing for Q3 2020, filed 13 Nov 2020.